Humira is a brand-name drug prescribed to treat rheumatoid arthritis, psoriatic arthritis, and more. It can remain unrefrigerated for up to 14 days, as long as the temperature doesn’t go above 77°F ...

At least one Big Apple resident was among 10 people hospitalized with “severe” illness in the US after injecting Botox bought from unlicensed sources through social media this year, officials said ...

As AbbVie Inc. ABBV looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant’s future growth, analysts say. When ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...